We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · January 28, 2021

Cytoreductive Surgery With or Without Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases

The Lancet Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

The Lancet Oncology
Cytoreductive Surgery Plus Hyperthermic Intraperitoneal Chemotherapy Versus Cytoreductive Surgery Alone for Colorectal Peritoneal Metastases (PRODIGE 7): A Multicentre, Randomised, Open-Label, Phase 3 Trial
Lancet Oncol 2021 Jan 18;[EPub Ahead of Print], F Quénet, D Elias, L Roca, D Goéré, L Ghouti, M Pocard, O Facy, C Arvieux, G Lorimier, D Pezet, F Marchal, V Loi, P Meeus, B Juzyna, H de Forges, J Paineau, O Glehen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading